肿瘤坏死因子(TNF)是一种细胞因子,在引发炎症反应中起重要介导作用,其抑制剂如英夫利昔单抗、阿达木单抗、依那西普,被相继批准用于慢性免疫性疾病如风湿性关节炎的治疗。戈利木单抗注射剂(golimumab)是一种新型TNF-α阻滞剂,与同类药物相比,其药理活性强,每月1次皮下注射给药更加方便。本文对其作用机制、药动学研究、临床试验、安全性评价等进行归纳总结。 Tumor necrosis factor (TNF) is a cytokine that plays an important mediating role in initiating inflammatory responses. Inhibitors such as infliximab, adalimumab, and etanercept have been approved for chronic immunization Treatment of sexually transmitted diseases such as rheumatoid arthritis. Golimumab is a new TNF-α blocker that is more pharmacologically active than its counterparts and administered subcutaneously once per month. This article summarizes its mechanism of action, pharmacokinetic studies, clinical trials, safety evaluation and so on.